Haige Shen

机构：Shanghai Genon Biological Products (China)

发表论文 18 篇 · 总被引 1009 次 · h-index 9

代表论文

• Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer (2020 · Nature Medicine · 被引 546)
• Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema (2014 · Ophthalmology · 被引 315)
• KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC. (2024 · Journal of Clinical Oncology · 被引 26)
• A phase I randomized, double‐blinded , placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects (2023 · Clinical and Translational Science · 被引 22)
• A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). (2023 · Journal of Clinical Oncology · 被引 20)
• First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors (2024 · BMC Cancer · 被引 17)